BRCA1 and cancer: Our investingations consistently show across all the clinical TNBC and OvCa cohorts examined that BRCA1meth cancers indeed have a lower objective response to platinum compounds than BRCA1mut cancers despite the association of BRCA1 promoter methylation with a reduction in BRCA1 RNA and with patterns of TDP type 1 formation identical to those found in BRCA1mut cancers.